Back to Search
Start Over
Docetaxel or abiraterone in addition to androgen deprivation therapy in metastatic castration-sensitive prostate cancer.
- Source :
-
Future oncology (London, England) [Future Oncol] 2017 Sep; Vol. 13 (22), pp. 1911-1913. Date of Electronic Publication: 2017 Aug 22. - Publication Year :
- 2017
Details
- Language :
- English
- ISSN :
- 1744-8301
- Volume :
- 13
- Issue :
- 22
- Database :
- MEDLINE
- Journal :
- Future oncology (London, England)
- Publication Type :
- Editorial & Opinion
- Accession number :
- 28829190
- Full Text :
- https://doi.org/10.2217/fon-2017-0270